NaseemaGangatMD

Instructor, Internal Medicine, Mayo Medical School

Dr. Gangat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2010
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2004 - 2007
Aga Khan Medical CollegeClass of 2002

Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Roles: Contact

PubMed

When and how to transplant in myelofibrosis - recent trends.
Naman Sharma, Giuseppe G Loscocco, Naseema Gangat, Paola Guglielmelli, Animesh Pardanani
Leukemia & Lymphoma. 2025-03-01
1 citations
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases.
Patricia Carey, Animesh Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat
American Journal of Hematology. 2025-03-01
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms.
Ayalew Tefferi, Naseema Gangat
American Journal of Hematology. 2025-02-11

Journal Articles

MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal
Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature
Determinants of Long-Term Outcome in Type 1 Calreticulin-Mutated Myelofibrosis
Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature